ArticleStem cell research & therapy2025
Targeted chondrogenic differentiation of human MSCs using niosomes for SOX9 gene delivery: comparison of minicircle and conventional plasmids.
Article in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundNiosomes represent a promising non-viral gene delivery system, offering an alternative to viral vectors for the genetic modification of hard-to-transfect cells, such as mesenchymal stem cells (MSCs), which are pivotal in regenerative medicine. Specifically, SOX9 gene transfer is a valuable strategy for cartilage tissue repair, as it promotes chondrocyte differentiation while repressing hypertrophic and osteogenic markers. In this study, we investigated the potential of niosomes to deliver SOX9, using both parental and minicircle plasmids, to induce chondrogenic differentiation in primary bone marrow-derived human MSCs (hMSCs).
methodsNiosomes were synthesised using the thin-film hydration method and complexed with either parental or minicircle SOX9 plasmids to form nioplexes. Physicochemical properties of niosomes and nioplexes were studied in terms of size, zeta potential, complexation, and protection capacity. Primary hMSCs were transfected in a 2D monolayer and 3D aggregate cultures using Lipofectamine as a positive control of transfection. Chondrogenic differentiation was assessed by gene expression (SOX9, ACAN, COLII, COLI, COLX), histological and immunohistochemical staining (Toluidine blue, haematoxylin & eosin and SOX9, COLII, COLI, COLX, respectively), and biochemical (proteoglycans, DNA and protein contents) analyses of main cartilage markers.
resultsSOX9 delivery via DP20CQ niosome systems significantly enhanced the expression of key chondrogenic markers (SOX9, ACAN, and COLII) and increased production of a characteristic hyaline-like cartilage matrix. In contrast, Lipofectamine-based complexes induced hypertrophic and fibrocartilaginous phenotypes, evidenced by increased expression of COLX and COLI. Quantification of proteoglycan production, along with proteins and DNA content, supported these findings. Both plasmid types promoted comparable chondrogenic outcomes, but parental plasmids yielded more consistent results than minicircles.
conclusionsDelivery of SOX9 plasmids via niosomes promotes enhanced chondrogenic differentiation of primary hMSCs in a 3D aggregate culture system, leading to the formation of hyaline-like cartilage tissue. This non-viral strategy represents a promising gene delivery platform for cartilage reparative therapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.